Published in Health Business Week, February 2nd, 2007
This decision was taken by the Ascend trial's steering committee based on a recommendation from the Data Safety Monitoring Board to stop the trial, following a significant imbalance in fluid retention in patients among the study arms. The company is informing health authorities including the U.S. Food and Drug Administration (FDA) and is in the process of notifying all clinical investigators in the trial.
The company also said that the compound will be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.